EluNIR Ridaforolimus Eluting Coronary Stent System
Medinol, Ltd. · Decision date Oct 2, 2025
What did the FDA approve?
FDA records P170008/S056 as a supplement to PMA P170008, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Oct 2, 2025.
FDA approval order statement
a sampling plan that reduces sample size of the incoming inspections for raw materials and components of the EluNIR-PERL Ridaforolimus Eluting Coronary Stent System
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 2, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P170008/S056
- Regulatory pathway
- PMA supplement
- Applicant
- Medinol, Ltd.
- Product code
- NIQ
- Decision code
- APPR
- Decision date
- Oct 2, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Medinol, Ltd.
- Product code
- NIQ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P170008/S056 received
Application receipt date recorded by FDA.
P170008/S059 · Related supplement
EluNIR-PERL Ridaforolimus Eluting Coronary Stent System
P170008/S060 · Related supplement
EluNIR Ridaforolimus Eluting Coronary Stent System
P170008/S056 · FDA decision
135 Review Track For 30-Day Notice
P170008/S061 · Related supplement
EluNIR Ridaforolimus Eluting Coronary Stent System
P170008/S062 · Related supplement
EluNIR Ridaforolimus Eluting Coronary Stent System
P170008/S064 · Related supplement
EluNIR Ridaforolimus Eluting Coronary Stent System
Timeline entries are records held by MedtechLedger for P170008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medinol, Ltd. | PMA supplement | Aug 7, 2025 | FDA | |
| Medinol, Ltd. | PMA supplement | Aug 15, 2025 | FDA | |
| Medinol, Ltd. | PMA supplement | Feb 4, 2026 | FDA | |
| Medinol, Ltd. | PMA supplement | Mar 26, 2026 | FDA | |
| Medinol, Ltd. | PMA supplement | Aug 6, 2026 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA supplement | Oct 16, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S066 | Biotronik AG | PMA supplement | Sep 24, 2026 | FDA |
| Abbott Vascular | PMA supplement | Aug 28, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medinol, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Kiryat Atidim, Bldg. 8, P.O.B. 58165, Tel Aviv, 6158101
Sources and methodology
- Original FDA record: P170008/S056
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




